Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Figures & data

Figure 1 Clear cell RCC represents the majority of all RCC tumors.

Abbreviation: RCC, renal cell carcinoma.

Table 1 Summary of the adverse events for sunitinib and bevacizumab plus IFN

All grade (%)	Sunitinib	Bevacizumab plus IFN
Fatigue	51	33
Diarrhea	53	20
Nausea	44	NR
Stomatitis	25	–
Hand-foot syndrome	20	–
Hypertension	24	26
Bleeding	12	33
Thrombocytopenia	65	6
Anemia	71	10
Proteinuria	–	18

Abbreviation: IFN, interferon alpha-2a; NR, not reported.

Figure 2 Lowering the dose of IFN improves tolerability.

Abbreviation: IFN, interferon alpha-2a.

Figure 3 Bevacizumab plus lower-dose IFN has a similar PFS to the total study population receiving bevacizumab plus IFN.

Abbreviations: PFS, progression-free survival; IFN, interferon alpha-2a.

Figure 4 Bevacizumab is a good partner for combination therapy.

Abbreviations: NK, not known; IFN, interferon alpha-2a.